Key findings

  • 20-30%of patients on continuous daily hydroxyurea develop resistance or intolerance, needing a change to second-line drugs
  • 20-30mg/Kghydroxyurea given as a single dose twice or thrice weekly: the intermittent regimen used at the authors' Centre
  • 118patients on intermittent hydroxyurea for 1-30 years (median 8.5 years), with notable absence of resistance or intolerance
  • 3patients with essential thrombocythemia referred as resistant to continuous hydroxyurea all responded to the intermittent schedule

Abstract

Twenty to 30% of patients with myeloproliferative neoplasms are known to experience resistance or intolerance to the commonly used continuous hydroxyurea therapy (500-1000mg daily, titrated based on response), necessitating change over to second-line therapeutic agents. At our Centre, we have used intermittent hydroxyurea therapy (20-30mg/Kg, given as a single dose twice or thrice weekly) and have observed sustained responses in 118 patients (polycythaemia vera-29, essential thrombocythemia-84, myelofibrosis-5) over a 30- year period (median 8.5 years), with notable absence of resistance or intolerance; this includes three patients who were previously considered to be resistant to hydroxyurea.

Based on the pharmacokinetics of hydroxyurea and our experience, we hypothesise that the intermittent single dose regimen enables selective cytotoxicity on treatment days (attributable to high plasma level and preferential uptake by the abnormal, proliferating cells) and normal haemopoiesis on the treatment-free days (hydroxyurea has a short plasma half-life). There has been no increase in the incidence of acute leukaemia in this cohort of patients.

We hope this review will encourage further evaluation of intermittent hydroxyurea therapy not only to circumvent resistance or intolerance, but also to improve the clinical outcomes in all patients with myeloproliferative neoplasms.

Introduction

Myeloproliferative neoplasms (MPN) are a group of chronic blood disorders resulting from abnormal, acquired somatic driver mutations (JAK-2, CALR, MPL) and non-driver mutations (ASXL 1, TET 2, SRSF 2) in the haemopoietic stem cells and uncontrolled, over production of red cells, white cells or platelets; the three classical Philadelphia-negative MPN include polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF); bone marrow fibrosis in patients with PMF is a reactive process attributable to overproduction of abnormal megakaryocytes and excessive release of cytokines.1–5 The incidence of each of these clinical entities ranges from 0.5 to 2.5 per 100,000.6 Patients with ET and PV can progress to myelofibrosis, termed post-ET myelofibrosis and post-PV myelofibrosis, respectively.7 Some patients with MPN with diagnostic molecular abnormalities may not meet the diagnostic haematological criteria for PV, ET or PMF; these patients are referred to as MPN-Unclassified.2 Thrombotic complications and disease progression are the common causes of death in MPN patients.8 Treatment of patients with these entities is mainly based on risk stratification and aimed at addressing disease-related symptoms, preventing thromboembolic events and normalising blood counts.9–11 Cytoreductive therapy is currently recommended in high-risk PV patients or low-risk patients with disease or treatment (phlebotomy)-related symptom burden;12 moderate or high-risk ET patients;13 and, PMF patients with splenic symptoms or high blood counts14. In all these patients, hydroxyurea (Hu) is the preferred first-line drug, given as continuous therapy at a dose of 500mg once or twice daily and titrated based on the response.14–16 The major limitation of this regimen is the occurrence of Hu resistance or intolerance in 20-30% of patients in all three sub-groups,14,17,18 necessitating change over to second-line cytoreductive therapy (e.g. interferon) or targeted therapy (e.g. ruxolitinib). Use of these second-line drugs may be limited by the high cost (especially in resource-poor countries), inconvenience of parenteral therapy (and sub-optimal patient compliance) or limited access to the drug. In this article, we review the literature relating to Hu-resistance or intolerance and discuss the notable absence of resistance/intolerance with intermittent Hu therapy which has been used at our Centre for more than 30 years; we also discuss the rationale for the use of the intermittent dosage regimen and its potential to improve clinical outcomes in MPN patients.

Hydroxyurea: Pharmacology and Pharmacokinetics19–23

Hydroxyurea is a structural analogue of urea and an S-phase cell cycle-specific ribonucleotide reductase inhibitor and nucleotide depleting agent, impacting on de novo DNA synthesis. Animal studies indicate that the cytotoxic effects are limited to those tissues with high rates of cellular proliferation and cells that are actively synthesising DNA.

More than 80% of the orally administered dose is readily absorbed and the peak plasma levels are reached in 1-4 hours. Studies have shown that higher plasma levels are achieved if Hu is given as a single large dose, than if it is given in divided doses. The plasma half-life is 2-4 hours. Up to 50% of the orally administered dose of Hu is metabolised in the liver and is excreted as respiratory carbon dioxide and in the urine as urea. The remaining portion is excreted intact in the urine.

Continuous Hydroxyurea Therapy, Resistance/Intolerance

Hu was introduced as a therapeutic agent for MPN patients in the 1980s.24 Since then it has become the preferred first-line cytoreductive drug, commonly given as continuous therapy at a daily dose ranging from 500mg to 3000mg.16,,25–28 The daily dosage regimen is probably the legacy of its predecessor, busulphan. Whilst documenting the therapeutic efficacy of Hu, several reports described marked oscillation of blood counts, the need for treatment interruption and sub-optimal or lack of sustained response in some patients.29–31 Twenty to 30% of MPN patients are now known to experience these features whilst receiving the continuous Hu therapy and are referred to as Hu-resistant (failure to control blood counts or spleen size) or Hu-intolerant (developing leg ulcers, mouth ulcers or significant cytopenias).32 Hu-resistance is attributable to inadequate dosage, high cell tumour or mutation burden, or alternate molecular pathway (e.g. TP53 and splicing factor mutation).33 Hu-intolerance is attributable to the side effects associated with the dosage of Hu therapy. Patients with PV or ET who experience Hu-resistance or intolerance are at increased risk of disease progression, progression to myelofibrosis, transformation to acute leukaemia, increased risk for thrombosis and reduced survival.17,32–36 One study has also documented a higher incidence of mental health issues and higher overall health-care costs in patients with Hu-intolerance.34

The current recommendations for second-line therapy for Hu-resistant or intolerant patients include long-acting interferon (Pegylated interferon, Ropeginterferon), anagrelide (for ET), JAK-2 inhibitor (e.g. Ruxolitinib) and the hepcidin mimetic, Rusfertide (for PV).37–44

Intermittent Hydroxyurea Therapy

In the late 1980s and early 1990s, we treated a few patients with MF with intermittent Hu: 20-30mg/Kg, given as a single dose twice or thrice weekly; this dosage schedule is akin to that used in patients with solid tumours. The treatment was well tolerated, safe and effective.45,46 Based on this favourable experience, we have used the intermittent Hu regimen in all our MPN patients at our Centre over the past 30 plus years.

A total of 120 patients had been treated with intermittent Hu therapy. Two patients developed febrile reaction to Hu, necessitating cessation of treatment. The other 118 patients (PV-29, ET-84, PMF-5) have continued Hu therapy for 1-30 years (median 8.5 years); PV – 10.8 years; ET – 7.75 years; PMF – 6 years. Molecular studies showed a positive result for JAK-2 in 87 patients (PV-27, ET-56, PMF-4); CALR mutation was noted in 17 patients (ET-16, PMF-1); MPL mutation was noted in 3 ET patients. The mean age of patients in the three disease sub-groups was 65.5 years, 63.1 years and 69.2 years, respectively. Treatment was well tolerated. The responses (resolution of disease-related symptoms and normal or near-normal blood counts) were sustained and not associated with cytopenias or muco-cutaneous ulcers. Accordingly, patients have continued the treatment over long periods of time.47

Three of the 84 ET patients were referred to our Centre because of Hu-resistance on continuous therapy at the dose of 500-1000mg daily; their total Hu dose per week was 6.5gms, 7gms and 4gms, respectively. All three responded to intermittent dosage schedule comprising total Hu dose per week at 6gms, 5gms and 3gms, respectively. At the time of the report, all three patients were well with sustained responses at 6 years, 11 years and 4½ years, respectively.47

Treatment of three PV patients was changed over to pegylated interferon at 8 years, 10 years and 16 years, respectively, because of increasing Hu dosage requirements. Similarly, three ET patients were changed over to pegylated interferon at 5 years, 17 years and 22 years, respectively, because of increasing Hu dosage requirements. Ruxolitinib was added to Hu therapy in four patients; PV-1, ET-2, PMF-1, for symptom control or changes suggestive of progression to myelofibrosis. Three of the 118 patients developed acute leukaemia at 5 years, 8 years and 16 years and succumbed after a short clinical course.47

All MPN patients at our Centre routinely undergo laboratory based (whole blood platelet aggregation studies) risk assessment for thrombosis and receive individualised anti-platelet therapy.48 In a study of 132 patients, we have documented varying degrees of platelet hyperactivity in 125 patients and a thrombosis-free survival of 1-23 years (median 8 years), whilst on the individualised anti-platelet therapy; no significant differences were noted in terms of aspirin dose requirements (ranging from 100mg twice or thrice weekly to 400mg daily) between JAK-2, CALR and MPL mutation patients and among the four IPSET-Thrombosis sub-groups.49,50

Recently we reported regression of post-essential thrombocythemia myelofibrosis (CALR positive) with intermittent Hu therapy in a 56-year-old lady, who was previously considered to be Hu-resistant/intolerant at another institution after the diagnosis of ET five years earlier.51 Her clinical features at presentation to our Centre comprised persistent thrombocytosis, anaemia and dense bone marrow fibrosis. Intermittent Hu therapy (20mg/Kg, given as a single dose thrice weekly) achieved improvement of all three parameters.51 She remains well, with stable blood counts at 3½ years after commencement of treatment at our Centre.

The take-home message from our single centre experience is that intermittent Hu therapy is well tolerated and effective (with notable absence of resistance/intolerance) over long periods of time; and that it complements the laboratory-based risk assessment for thrombosis and thromboprophylaxis. Prolonged use of Hu has not been associated with any increased incidence of acute leukaemia.52,53

Discussion

Hu remains as the preferred first-line therapeutic agent for cytoreduction in MPN patients despite the frequent and well documented occurrence of resistance or intolerance. The simplicity and convenience of Hu therapy make it the most patient friendly treatment. The low cost and free availability all over the world make Hu the most affordable option for MPN patients in resource-poor countries. Accordingly, it would remain as a “preferred option” even in patients with Hu-resistance or intolerance. This summation should resonate with Chen and colleagues (from Boston, USA) who recently reported limited transition to alternative cytoreductive therapy despite Hu-resistance or intolerance in a study comprising 767 patients with ET.54 Can the efficacy of Hu therapy be improved and the resistance/intolerance circumvented? The answer to these questions lies in better understanding of the pharmacokinetics of Hu.

The key points to note in Hu pharmacokinetics are: i) a bigger single dose achieves a higher plasma level – i.e. a 1000mg once daily dose is better than a 500mg twice daily dose; ii) the drug is preferentially taken in by the cells that are actively synthesising DNA – i.e. the abnormal, proliferating cells; iii) Hu has a short plasma half-life (2-4 hours) – i.e. the drug is rapidly excreted and so there will be no cytotoxic effect on treatment-free days. The intermittent Hu therapy (20-30mg/Kg, given as a single dose twice or thrice weekly) is better aligned to the above listed key points. Based on this discussion and our favourable experience over the past 30 plus years, we hypothesise that the intermittent dosage regimen enables a) selective cytotoxicity of the abnormal, proliferating cells on the treatment days and b) normal haemopoietic activity on the treatment-free days. The absence of Hu in the system on treatment-free days, also probably explains the notable absence of leg ulcers and oral ulcers in our cohort of patients.

Our favourable experience with the intermittent Hu therapy (including sustained responses in patients with history of Hu-resistance) and suggestion for its use in Hu-resistant/intolerant patients (and may be in all MPN patients) should be seen in the context of a) cost, convenience, patient compliance and global availability of the currently recommended second-line drugs for cytoreduction; and, b) the efficacy/adequacy of the current standard-of-care treatment of MPN patients.

Second-line cytoreductive therapy

Of the suggested therapeutic agents, Ropeginterferon and Rusfertide are not currently available in many countries, including Australia. Table 1 shows the comparative cost of the available and in-use cytoreductive agents.55 The substantial cost difference between Hu and the others is not an issue in Australia but will be a major consideration in countries where the patient must pay for his/her treatment. In the case of pegylated interferon, the need for weekly parenteral administration will add to the cost, as well as inconvenience which can impact on patient compliance. Table 2 shows the common side effects associated with the currently recommended therapeutic agents, including Hu.56 The only consistent abnormality in our 118 patients was red cell macrocytosis, a finding of no clinical significance; we did not observe any other side effect of concern.47

Table 1. Cost* of currently available cytoreductive drugs

Medicine NameUnitsCost /unit
Peginterferon alpha-2a
(Pegasys)
180microg
1 injection$265/injection
Hydroxyurea (Hydrea)
500mg
1 capsule$0.47/capsule
Ruxolitinib (Jakavi)
5mg
1 tablet$43/tablet
Ruxolitinib (Jakavi)
10mg
1 tablet$84/tablet
Ruxolitinib (Jakavi)
15mg
1 tablet$84/tablet
Ruxolitinib (Jakavi)
20mg
1 tablet$84/tablet
Anagrelide (Agrylin)
0.5mg
1 capsule$7.15/capsule

* Australian dollars

Table 2. Common side-effects associated with cytoreductive agents

MedicineCommon Adverse Effects (incidence >10%)
Ropeginterferon (Besremi ™)Cardiovascular: Oedema (16%), hypertension (16%, including hypertensive crisis)
Dermatologic: Alopecia (16%), hyperhidrosis (29%), pruritus (45%), skin rash (16%)
Gastrointestinal: Abdominal pain (20%), decreased appetite (18%), diarrhea (33%), nausea (28%)
Genitourinary: Urinary tract infection (16%; serious urinary tract infection: 8%)
Hematologic & oncologic: Leukopenia (18% to 20%; grades ≥3: 2%), neutropenia (16%), thrombocytopenia (12% to 19%; grades ≥3: 2%)
Hepatic: Increased serum transaminases (16% to 20%, including increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin)
Infection: Infection (48%; serious infection: 8%)
Local: Injection site reaction (26%)
Nervous system: Depression (≤20%; severe depression: 4%), dizziness (22%), fatigue (12% to 47%), headache (39%), sleep disorder (20%), vertigo (12%)
Neuromuscular & skeletal: Arthralgia (13% to 47%), muscle spasm (16%), musculoskeletal pain (41%), myalgia (11%)
Ophthalmic: Eye disease (23%)
Respiratory: Flu-like symptoms (11% to 59%), nasopharyngitis (43%), upper respiratory tract infection (27%)
PegInterferon alpha-2a (Pegasys™)Dermatologic: Alopecia (children and adolescents: 6%; adults: 18% to 23%), pruritus (12%)
Endocrine & metabolic: Growth suppression (children and adolescents: decrease >15 percentiles: weight [11% to 29%], height [6% to 18%])
Gastrointestinal: Abdominal pain (children, adolescents, and adults: 15% to 17%), anorexia (16% to 17%), diarrhea (16%), nausea (children and adolescents: 9%; adults: ≤24%), vomiting (children, adolescents, and adults: ≤24%)
Hematologic & oncologic: Neutropenia (severe: 21%)
Hepatic: Increased serum alanine aminotransferase (children and adolescents: 10%; adults: 12% to 27%)
Immunologic: Antibody development (29%; neutralizing: 13%)
Local: Injection-site reaction (22%)
Nervous system: Anxiety (≤19%), asthenia (children and adolescents: 9%; adults: ≤56%), depression (18%), dizziness (children and adolescents: 6%; adults: 16%), fatigue (children and adolescents: 8%; adults: ≤56%), headache (children and adolescents: 21%; adults: 27% to 54%), insomnia (19%), irritability (≤19%), nervousness (≤19%), pain (11%), rigors (35%)
Neuromuscular & skeletal: Arthralgia (28%), myalgia (26% to 37%)
Respiratory: Cough (children and adolescents: 15%; adults: 4%), flu-like symptoms (children and adolescents: 14%)
Miscellaneous: Fever (children, adolescents, and adults: 37% to 54%)
ruxolitinib (Jakavi™)Cardiovascular: Hypertension (5% to 16%)
Endocrine & metabolic: Hypercholesteremia (17% to 88%), hypertriglyceridemia (15%)
Gastrointestinal: Diarrhea (10% to 15%), increased serum amylase (35%), increased serum lipase (38%), nausea (6% to 12%)
Hematologic & oncologic: Anaemia (72% to 96%; grades 3/4: ≤34%), bruise (23%), haemorrhage (12%), neutropenia (3% to 19%; grades 3/4: ≤12%), thrombocytopenia (27% to 70%; grades 3/4: ≤20%)
Hepatic: Increased gamma-glutamyl transferase (81%), increased serum alanine aminotransferase (25% to 73%), increased serum aspartate aminotransferase (17% to 65%)
Infection: Infection (45%; including bacterial infection, fungal infection, mycobacterial infection, serious infection, viral infection [28%])
Nervous system: Dizziness (15% to 18%), fatigue (13%), headache (15%)
Neuromuscular & skeletal: Muscle spasm (12%), musculoskeletal pain (18%)
Renal: Increased serum creatinine (47%)
Respiratory: Cough (13%), dyspnoea (11% to 13%)
Miscellaneous: Fever (16%)
rusfertide (Mimrylo™)Hematologic & oncologic: Anaemia (16%)
Immunologic: Antibody development (34%; neutralizing: 36%)
Local: Injection-site reaction (47% to 56%; including erythema at injection site [27%], injection-site pruritus [17%], pain at injection site [15%], swelling at injection site [8%])
Hydroxyurea (Hydrea™)Dermatologic: Xeroderma (adults: 12%)
Hematologic & oncologic: Macrocytosis (mean corpuscular volume >97 fL: 42%), neutropenia (5% to 13%)
Infection: Bacterial infection (children, adolescents: 16%; adults: 4%), infection (40% to 43%; serious infection: 4% to 18%)
Nervous system: Headache (children, adolescents: 7%; adults: 20%)
Anagrelide (Agrylin™)Cardiovascular: Oedema (21%), palpitations (26%)
Gastrointestinal: Abdominal pain (16%), diarrhea (26%), nausea (17%)
Nervous system: Dizziness (15%), headache (44%), pain (15%)
Neuromuscular & skeletal: Asthenia (23%)
Respiratory: Dyspnoea (12%)

Current standard-of-care treatment

A relevant question related to this discussion is “How good is the current standard-of-care treatment?”. Review of some recent noteworthy publications prompt an answer “Not all that good” or “Needs improvement”! These articles have highlighted the very high incidence of persistent and troublesome disease and/or treatment-related symptom burden (impacting on the quality of life), sub-optimal disease control and/or persistent risk for thrombosis.57–61

In a nurse-led observational study, Berardinelli and colleagues reported substantial physical and psychosocial symptom burden in 85% of MPN patients; the symptoms included fatigue (72%), anxiety (42%), depression (44%), inactivity, pain, itching and abdominal discomfort.58 In the GIMEMA-PROPHECY study of 572 patients (PV-207, ET-228, PMF-137), Caocci and colleagues reported similar findings and impaired health-related quality of life; these authors also noted substantial underestimation of disease/treatment-related symptoms by the treating haematologists.59

In a recently published retrospective claims-based study, Gerds and colleagues analysed clinical outcomes in 11,311 PV patients, treated over an 11-year period (median follow-up 2.8 years). The disease was classified as high-risk in 51.8% of patients and low-risk in 48.2%, all receiving the recommended standard-of-care treatment. They recorded troublesome symptoms in 83.3% of patients, a haematocrit level >45% in 85.3% of patients and thromboembolic events in 15.3 % of patients; 9.6% of patients had iron deficiency and disease progression was noted in 4.4%. They also reported the very high cost of care (more than 71,000 USD) associated with a thromboembolic event. The authors concluded that the current standard-of-care therapies (phlebotomy, cytoreductive therapy) do not consistently maintain haematocrit level <45%, leading to life-threatening and costly thromboembolic events; and emphasised the need for more effective therapeutic strategies for better disease control and mitigate the overall PV burden.60

In another, even larger observational study comprising 20,089 PV patients, Kuykendall and colleagues noted persistent risk for thromboembolic events in both high-risk (event based -50%, age-based -25%) and low-risk (13%) patients despite therapy; they also noted that each 1% increase in haematocrit was associated with 0.3% increase in thromboembolic events, highlighting the need for improved therapies to reduce the risk of the latter and other cardiovascular events.61 Persistent risk for thromboembolism, especially in high-risk PV patients has also been noted by Manz and colleagues from Germany, who have iterated the need for therapy optimisation.62 A clue to achieve the latter has emerged from a nation wide population study from Sweden by Enblom and colleagues.63

In the Swedish study,63 the authors assessed the risk of thrombosis, bleeding and all-cause-mortality (ACM) in 5745 patients (PV-2604, ET-3141) and noted that advanced age and leucocytosis were associated with higher incidence of thrombosis, bleeding and ACM. Patients receiving Hu or interferon had reduced risk for ACM; Hu therapy was also associated with reduced incidence of thrombosis and bleeding. Interestingly, they noted a “higher- than -expected” use of Hu in low-risk patients. They concluded by suggesting further studies to determine appropriate timing for initiation of cytoreductive therapy. The reduced incidence of ACM in patients receiving Hu or interferon in this Swedish study is highly suggestive of a beneficial effect on the cardiovascular system. Cardiovascular and microvascular complications are underestimated as interdependent comorbidities in patients with MPN. Schafer and Mann in their narrative review have suggested that the two entities (i.e. MPN and cardiovascular disease) may adversely impact on each other in a “vicious cycle”.64

The take-home message from all these studies is that the current standard-of-care treatment for MPN needs urgent review; and that consideration should be given for a more active and effective therapeutic approach.

Conclusion

Intermittent Hu therapy is better aligned to Hu pharmacokinetics, than the commonly used continuous therapy regimen; and has shown sustained responses, with notable absence of resistance or intolerance, over long periods. We hope that this review will encourage further evaluation of intermittent Hu therapy, not only to circumvent resistance or intolerance but also to achieve better disease control and improve clinical outcomes in MPN patients; and show that we have progressed from the times of Voltaire (the 18th century French author) who said “Doctors are men who prescribe medicines of which they know little, to cure diseases of which they know less, in human beings of whom they know nothing”!65

Declarations

Author Contribution
AM wrote the manuscript; SIE prepared the Tables.
Conflicts of Interest Statement
No conflict of interest
Funding Statement
No external funding

References

  1. Dickstein JL, Vardiman JW. Hematopathologic Findings in The Myeloproliferative Disorders. Semin Oncol.1995; 22(4):355-373.
  2. Tremblay D, Yacoub A, Hoffman R. Overview of MPNs: History, Pathogenetic Criteria and Complications. Hematol Oncol Clin North Am. 2021; 35(2): 155-176.
  3. Thiele J, Kvasnicka HM, Orazi A, et al. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemia. Myeloproliferative Neoplasms. Am J Hematol. 2023; 98:166-179.
  4. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic Myeloid Metaplasia: A Clonal Proliferation of Hemopoietic Stem Cells with Secondary Myelofibrosis. Blood, 1978; 51:189-194.
  5. Zahr AA, Salama ME, Correau N, et al. Bone Marrow Fibrosis in Myelofibrosis: Pathogenesis, Prognosis and Targeted Strategies. Hematologica, 2016; 101: 660-671.
  6. Ma X, Zhou Z, Gu S, et al. Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms. Cancers, 2025; 17(19): 3142.
  7. Barosi G, Mesa RA, Thiele J, et al. Proposed Criteria for The Diagnosis of Post-polycythemia Vera and Post-essential Thrombocythemia Myelofibrosis – A Consensus Statement from The International Working Group for Myelofibrosis Research and Treatment. Leukemia, 2008; 22(2): 437-438.
  8. Mesa RA, Miller CB, Thyne M, et al. Differences in Treatment Goals and Perception of Symptom Burden Between Patients with Myeloproliferative Neoplasms(MPNs) and Hematologists/Oncologists in The United States: Findings from The MPN Landmark Survey. Cancer, 2017; 123(3): 449-458.
  9. Tefferi A. Primary Myelofibrosis. 2023 Update on Diagnosis, Risk Stratification and Management. Am J Hematol. 2023; 98: 801-823.
  10. Gerds AT, Gotlib J, Ali H, et al. Myeloproliferative Neoplasms, Version 3 2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022; 20: 1033-1082.
  11. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia Chromosome Negative Classical Myeloproliferative Neoplasms: Revised Management Recommendations from European Leukemia NET. Leukemia, 2018; 32: 1057-1069.
  12. Barosi G, Tefferi A, Besses C, et al. Clinical End Points for Drug Treatment Trials in BCR-ABL 1-Negative Classic Myeloproliferative Neoplasms: Consensus Statement from European Leukemia NET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia, 2015; 29: 20-26.
  13. Samuelsson J, Hasseibalch H, Bruserud O, et al. A Phase 2 Trial of Pegylated Interferon Alfa-2b Therapy for Polycythaemia Vera and Essential Thrombocythemia: Feasibility, Clinical and Biologic Effects, and Impact on Quality of Life. Cancer, 2006; 106; 2397-2405.
  14. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and Tolerability of Hydroxyurea in The Treatment of the Hyperproliferative Manifestations of Myelofibrosis: Results in 40 Patients. Ann Hematol. 2010; 89: 1233-1237.
  15. Vanncchi AM. How I Treat Polycythemia Vera. Blood, 2014; 124(22): 3212-3220.
  16. Tefferi A, Vannucchi AM, Barbui T. Essential Thrombocythemia: 2024 Update on Diagnosis, Risk Stratification and Management. Am J Hematol. 2024; 99(4): 697-718.
  17. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, et al. Frequency and Prognostic Value of Resistance/Intolerance to Hydroxycarbomide in 890 Patients with Polycythaemia Vera. Br J Haematol. 2016; 172(5): 786-793.
  18. Rumi E, Cazzola M. How I Treat Essential Thrombocythemia. Blood, 2016; 128(20): 2404-2414.
  19. Young CW, Schochetman G, Karnovski DA. Hyroxyurea-induced Inhibition of Deoxy-ribonucleotide Synthesis: Studies in Intact Cells. Cancer Res. 1967; @7: 526-529.
  20. Wawra E, Wintersberger E. Does Hydroxyurea Inhibit DNA Replication in Mouse Cells by More Than One Mechanism? Mol Cell Biol. 1983; 3: 297-304.
  21. Tracewell WB, Trump DL, Vaughan WP, et al. Population Pharmacokinetics of Hydroxyurea in Cancer Patients. Cancer Chemother Pharmacol. 1995; 35: 417-422.
  22. Gwilt PR, Tracewell WG. Pharmacokinetics and Pharmaco-dynamics of Hydroxyurea. Clin Pharmacokinet. 1998; 34(5): 347-358.
  23. McEvoy GK. AHFS Drug Information. Oncology Issues, 1994; 9(5): 12-13.
  24. Spivak JL, Hasselbalch H. Hydroxycarbomide: A User’s Guide for Chronic Myeloproliferative Disorders. Expert Rev Anticancer Ther. 2011; 11(3): 403-414.
  25. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of Polycythemia Vera with Hydroxyurea. Am J Hematol. 1984; 17(4): 329-334.
  26. Fruchetman SM. From Efficacy to Safety: A Polycythemia Vera Study Group Report on Hydroxyurea in Patients with Polycythemia Vera. Semin Hematol. 1997; 34: 17-23.
  27. Cortelazzo S, Finazzi G, Rugger M, et al. Hydroxyurea for Patients with Essential Thrombocythemia and High Risk for Thrombosis. N Engl J Med. 1995; 332(17): 1132-1137.
  28. Lofvenberg E, Wahlin A. Management of Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis with Hydroxyurea. Eur J Haematol. 1998; 41(4): 375-381.
  29. Tefferi A, Elliott MA, Kao PC, et al. Hydroxyurea-induced Marked Oscillations of Platelet Counts in Patients with Polycythemia Vera. Blood, 2000; 96(4): 1582-1584.
  30. Tauscher J, Siegel F, Petrides PE. Hydroxyurea Induced Oscillations in Twelve Patients with Polycythemia Vera. Haematologica, 2010; 95(7); 1227.
  31. Dom MJ, Pedersen RK, Knudsen TA, et al. Data-driven Analysis of The Kinetics of The JAK-2V617F Allele Burden and Blood Counts During Hydroxyurea Treatment of Patients with Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis. Eur J Haematol. 2021; 107(6): 624-633.
  32. Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, et al. Clinical Evaluation of The European LeukemiaNET Criteria for Clinicohaematological Response and Resistance/Intolerance to Hydroxybromide in Essential Thrombocythemia. Br J Haematol. 2011; 52(1): 81-88.
  33. Park YH, Lee S, Mun Y, et al. Prognostic Value of Modified Criteria for Hydroxyurea Resistance or Intolerance in Patients with High-risk Essential Thrombocythemia. Cancer Med. 2023; 12(7): 8073-8082.
  34. Ellis MH, Tadmor T, Yekutiel N, et al. Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice. J Clin Med. 2024; 13(12): 3390.
  35. Santaliestra M, Garrote M, Noya MS, et al. Prognostic Value of Response to First-line Hydroxyurea According to IPSET Stratification in Essential Thrombocythemia. Leukemia, 2024; 38(12): 2636-2643.
  36. Kuykendall AT. Treatment of Hydroxyurea-resistant/intolerant Polycythemia Vera: A Discussion of Best Practice. Ann Hematol. 2023; 102(5): 985-993.
  37. Sever M, Newberry KJ, Verstovsek S. Therapeutic Options for Patients with Polycythemia Vera and Essential Thrombocythemia Refractory/Resistant to Hydroxyurea. Leuk Lymphoma. 2014; 55(12): 2685-2690.
  38. Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea: Long-term Phase 2 Study Results. Blood, 2017; 130(15): 1768-1771.
  39. Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated Interferon alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. Blood, 2019; 134(18): 1498-1509.
  40. How J, Hobbs G. Use of Interferon Alfa in The Treatment of Myeloproliferative Neoplasms: Perspectives and Review of The Literature. Cancers (Basei), 2020; 12(7): 1954.
  41. Yoon SY, Lee S. Treatment with Ropeginterferon Alfa-2b in Patients with Hydroxyurea Resistant or Intolerant Polycythemia Vera in South Korea: One-year Results from A Phase 2 Study. Blood Res. 2024; 59(1): 23
  42. Lee S. Yoon SY, Kim S, et al. A Comparative Study of Hematologic Response to Ropeginterferon Alfa-2b in Hydroxyurea-resistant or Intolerant Polycythemia Vera: A Real -World Data-based Analysis. Blood Res. 2025; 60(1): 61
  43. Reeves BN, Chaer FE, Foltz L, et al. Ropeginterferon Alfa-2b-njft Treatment in Essential Thrombocythemia Across Different Driver Mutations: Results from A North American Single Arm, Multicentre Study (EXCEED-ET). Lancet, 2026; 61:101529.
  44. Chen LP, Ginzburg YZ, Kirubamoorthy K, et al. Rusfertide Rapidly Decreases Hematocrit in Patients with Suboptimally Controlled Polycythemia Vera. Leukemia Res., 2025; 159: 108132.
  45. Manoharan A. Myelofibrosis: Prognostic Factors and Treatment. Br J Haematol. 1988; 69(3): 295-298.
  46. Manoharan A. Management of Myelofibrosis with Intermittent Hydroxyurea. Br J Haematol. 1991; 77(2): 252-254.
  47. Manoharan A, Enggist SI. Hydroxyurea: An Old Drug in Need of New Clinical Trials in Myeloproliferative Neoplasms? Int Internal Med J. 2024; 2(9): 1-6.
  48. Manoharan A, Gemmell R, Cavanaugh L, et al. Thrombosis in Myeloproliferative Neoplasms: A Single Centre Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis. Clin Appl Thromb/Hemost. 2022; 28: 10760296221117482.
  49. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant Revision of IPSET-Thrombosis Based on 1019 Patients with WHO-defined Essential Thrombocythemia. Blood Cancer J. 2015; 5: e369.
  50. Haider M, Gangat N, Lasho T, et al. Validation of The Revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-Thrombosis) in 585 Mayo Clinic Patients. Am J Hematol. 2016; 91:390-394.
  51. Manoharan A, Tang I. Regression of Post-essential Thrombocythemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report. J Clin Med. 2025; 14(24): 8641.
  52. Tefferi A, Rumi E, Finazzi G, et al. Survival and Prognosis Among 1545 Patients with Contemporary Polycythemia Vera: An International Study. Leukemia, 2013; 27(9): 1874-1881.
  53. Wang R, Shallis RM, Stempel JM, et al. Second Malignancies Among Older People with Classical Myeloproliferative Neoplasms Treated with Hydroxyurea. Blood Adv., 2023; 7(5): 734-743.
  54. Chen E, Yang Y, Obeng-Kusi M, et al. Real-World Clinical Burden Among Patients with Essential Thrombocythemia Who Develop Resistance or Intolerance to Hydroxyurea. European Hematology Association 2026 Congress. Abstract EHA 3150.
  55. Australian Government, Department of Health and Aged Care, Pharmaceutical Benefit Scheme; 2026.
  56. Drug Monographs [Internet] In: UpToDate Lexidrug [Internet] Waltham (MA): Wolters Kluwer; 2026.
  57. Visweshwar N, Fletcher B, Jaglal M, et al. Impact of Phlebotomy on Quality of Life in Low-risk Polycythemia Vera. J Clin Med. 2024; 13(16): 4952.
  58. Berardinelli D, Fava C, Bonuomo V, et al. Nurse-led Patient Reported Outcome Assessment of Symptom Burden and Quality of Life in Myeloproliferative Neoplasms: An Observational Study. Nursing Open, 2026; 13(9): e70784.
  59. Caocci G, Costa A, Palandri F, et al. Health-related Quality of Life and Symptom Profile of Patients with BCR:ABL 1 -Negative Myeloproliferative Neoplasms: Real-World Evidence from the GIMEMA-PROPHECY Observational Study. HemaSphere, 2025; 9(12): e70274.
  60. Gerds AT, Fan Q, Jerry M, et al. Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study. J Blood Med. 2026; 2026: 17626464.
  61. Kuykendall AT, Molina A, Reaven N, et al. Risk of Thromboembolic Events in Patients with Polycythemia Vera: A Real-World Observational Study. Clin Lymphoma Myeloma Leuk. 2026; 26(8): 549-561.
  62. Manz R, Morouj B, Feuerbach M, et al. Risk of Thromboembolic Events in Patients with Polycythemia Vera: A Study Based on German Health Claims Data. Ann Hematol. 2026; 105: 301.
  63. Enblom A, Renlund H, Andreasson B, et al. Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival. Eur J Haematol. 2026; 116(5): 545-557.
  64. Schafer AI, Mann DL. Thrombotic Cardiovascular and Microvascular Complications of Myeloproliferative Neoplasms and Clonal Haematopoiesis (CHIP): A Narrative Review. J Clin Med. 2024; 13(22): 6957.
  65. Voltaire. In Best Quotations for All Occasions, Ed. Lewis C. Henry, 1990; 288.

Article information

Authors

How to cite

Manoharan, A., Enggist, S. I., 2026. Hydroxyurea Therapy for Myeloproliferative Neoplasms: Intermittent Dosage Can Circumvent Resistance/Intolerance. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0669

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
92

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.